KẾT QUẢ ĐIỀU TRỊ DOXETAXEL SAU HÓA CHẤT PHÁC ĐỒ PACLITAXEL- CARBOPLATIN TRONG UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV TẠI BỆNH VIỆN K

Abstract

Aims: To evaluate the results of docetaxel maintenance therapy after paclitaxel- carboplatin chemotherapy in stage IV non-small cell lung cancer. Patients and methods: A retrospective combined prospective study. The patient diagnosed at Vietnam National Cancer Hospital, from June 2016 to June 2022  with stage IV non-small cell lung cancer from 6/2016 to 6/2022 after step 1 treatment with paclitaxel - carboplatin chemotherapy duo achieved response or stable disease. The assessment was recorded clinical symptoms, subclinical, treatment methods, assessment of survival time and related factors. Results: The study was carried out on 55 patients. The median age of patients was 62 years old, of which male accounted for 82.1%; Common functional symptoms are dry cough (37.5%), chest pain (32.1%), dyspnea (16.1%); Common sites of metastasis are contralateral lung, bone (26.8%), pleura (25%). There were 32 patients (58.2%) with partial response, 41.8% of patients with stable disease, no patient with complete response. Median progression-free survival was 4.2 months. Side effects: leukopenia is 38.1%, of which grade 3 and 4 leukopenia is 10.9%; Hemoglobin reduction accounted for 92.9%, mainly grade 1 and grade 2. The rate of mucositis accounted for 48.8% over the course of treatment, mainly transient, self-healing. Diarrhea accounts for 30.9%, mainly grade 1, self-healing. Conclusion: Docetaxel maintenance treatment after paclitaxel-carboplatin duo chemotherapy showed high efficacy, good drug tolerance in patients with stage IV non-small cell lung cancer.